This study is designed to evaluate the long-term safety and tolerability of REN001 administered once daily to subjects with PMM who have previously completed Study REN001-201 or participated in Study REN001-101 and withdrew from that study due to the COVID-19 pandemic.~Eligible subjects will be treated with REN001 100mg orally, once daily for 24 months. Following the baseline visit there are planned visits at at defined time points. A final follow-up telephone call will be made by the study centre to the subject approximately 30 days after the last dose of study drug.
This is a long-term safety and tolerability study. REN001 is administered once daily to subjects with PMM who have previously completed Study REN001-201 or participated in Study REN001-101 and withdrew from that study due to the COVID-19 pandemic.